Irene Rivera-Ruiz, Alberto Soto-Moreno, Miguel Mansilla-Polo, Patricia Garbayo-Salmons, Daniel Muñoz-Barba, César Guijarro-Sánchez, Alejandro Molina-Leyva
{"title":"Type 1 Diabetes is Associated With Increased Therapeutic Burden in Hidradenitis Suppurativa: A Multicenter Retrospective Matched Case-Control Study.","authors":"Irene Rivera-Ruiz, Alberto Soto-Moreno, Miguel Mansilla-Polo, Patricia Garbayo-Salmons, Daniel Muñoz-Barba, César Guijarro-Sánchez, Alejandro Molina-Leyva","doi":"10.1177/12034754261484189","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with multiple systemic comorbidities. Although its association with type 2 diabetes is well established, the clinical impact of coexisting type 1 diabetes (T1D) remains poorly defined.</p><p><strong>Objectives: </strong>To compare the clinical characteristics, disease burden, and therapeutic requirements of patients with HS and T1D with matched HS controls.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective matched case-control study across 3 tertiary dermatology departments. Patients with HS and confirmed T1D were matched 1:3 by age, sex, and baseline Hurley stage. Clinical and therapeutic outcomes were assessed over a standardized 48 week follow-up.</p><p><strong>Results: </strong>Twelve patients with HS and T1D and 33 matched controls were included. Baseline disease severity was comparable. During follow-up, patients with HS + T1D had higher mean International Hidradenitis Suppurativa Severity Score System scores (11.95 vs 6.24; <i>P</i> = .01), more draining tunnels (11.0 vs 3.97; <i>P</i> < .01), received more systemic treatments (4.10 vs 3.06; <i>P</i> = .03), and underwent more surgical procedures (1.67 vs 0.67; <i>P</i> < .01).</p><p><strong>Conclusions: </strong>Patients with HS and coexisting T1D may experience a greater inflammatory and therapeutic burden than matched controls. These findings support closer multidisciplinary management and warrant prospective studies to validate T1D as a potential modifier of HS severity.</p><p><strong>Limitations: </strong>Retrospective design and small sample size.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754261484189"},"PeriodicalIF":2.8000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Medicine and Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/12034754261484189","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with multiple systemic comorbidities. Although its association with type 2 diabetes is well established, the clinical impact of coexisting type 1 diabetes (T1D) remains poorly defined.
Objectives: To compare the clinical characteristics, disease burden, and therapeutic requirements of patients with HS and T1D with matched HS controls.
Methods: We conducted a multicenter retrospective matched case-control study across 3 tertiary dermatology departments. Patients with HS and confirmed T1D were matched 1:3 by age, sex, and baseline Hurley stage. Clinical and therapeutic outcomes were assessed over a standardized 48 week follow-up.
Results: Twelve patients with HS and T1D and 33 matched controls were included. Baseline disease severity was comparable. During follow-up, patients with HS + T1D had higher mean International Hidradenitis Suppurativa Severity Score System scores (11.95 vs 6.24; P = .01), more draining tunnels (11.0 vs 3.97; P < .01), received more systemic treatments (4.10 vs 3.06; P = .03), and underwent more surgical procedures (1.67 vs 0.67; P < .01).
Conclusions: Patients with HS and coexisting T1D may experience a greater inflammatory and therapeutic burden than matched controls. These findings support closer multidisciplinary management and warrant prospective studies to validate T1D as a potential modifier of HS severity.
Limitations: Retrospective design and small sample size.
背景：化脓性汗腺炎（HS）是一种慢性炎症性皮肤病，伴有多种全身合并症。尽管其与2型糖尿病的关系已得到证实，但共存的1型糖尿病（T1D）的临床影响仍不明确。目的：比较HS和T1D患者与匹配的HS对照组的临床特征、疾病负担和治疗需求。方法：我们在3个三级皮肤科进行了一项多中心回顾性匹配病例对照研究。HS和确诊T1D患者按年龄、性别和基线Hurley分期1:3匹配。在标准化的48周随访中评估临床和治疗结果。结果：纳入12例HS合并T1D患者和33例匹配对照。基线疾病严重程度具有可比性。在随访期间，HS + T1D患者的国际化脓性水疱炎严重程度评分系统平均评分更高(11.95 vs 6.24; P =。01)，更多排水隧道(11.0 vs 3.97; P P =。结论：HS合并T1D患者可能比对照组承受更大的炎症和治疗负担。这些发现支持更紧密的多学科管理，并支持前瞻性研究，以验证T1D作为HS严重程度的潜在调节剂。局限性：回顾性设计和小样本量。
期刊介绍：
Journal of Cutaneous Medicine and Surgery (JCMS) aims to reflect the state of the art in cutaneous biology and dermatology by providing original scientific writings, as well as a complete critical review of the dermatology literature for clinicians, trainees, and academicians. JCMS endeavours to bring readers cutting edge dermatologic information in two distinct formats. Part of each issue features scholarly research and articles on issues of basic and applied science, insightful case reports, comprehensive continuing medical education, and in depth reviews, all of which provide theoretical framework for practitioners to make sound practical decisions. The evolving field of dermatology is highlighted through these articles. In addition, part of each issue is dedicated to making the most important developments in dermatology easily accessible to the clinician by presenting well-chosen, well-written, and highly organized information in a format that is interesting, clearly presented, and useful to patient care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
